Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-11-Speech-2-367-562"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-09-11"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20120911.32.2-367-562"2
lpv:hasSubsequent	lp_eu:2012-09-11-Speech-2-367-6252
lpv:speaker	lp:Marielle de Sarnez2
lpv:spokenAs	member; INTA (2012-01-19--2014-06-30)3 substitute; AFET (2012-01-19--2014-06-30)3 substitute; Delegation to the Euro-Latin American Parliamentary Assembly (2009-09-16--2014-06-30)3 vice-chair; ALDE (2009-07-14--2014-06-30)3 unknown; Mouvement Démocrate (2009-07-14--2014-06-30)3 member; Delegation to the ACP-EU Joint Parliamentary Assembly (2009-09-16--2014-06-30)3 substitute; Delegation for relations with the countries of the Andean Community (2009-09-16--2014-06-30)3
lpv:translated text	"The Mediator health scandal will at least have served to make us aware of the overwhelming need to improve pharmacovigilance in Europe – that is, the surveillance of medicines and the prevention of the risk of undesirable effects, potential or actual, resulting from their use. In 2009, France decided to withdraw this medicine produced by the Servier laboratory, which caused the death of 500 to 2 000 people, according to estimates. Since 2003, it has been withdrawn from the market in Spain and in Italy, at the request of the laboratory. From now on, when a medicine is voluntarily withdrawn from the market in a Member State, the precautionary principle will apply, and the medicine will be temporarily or permanently withdrawn from the other European countries. Businesses will also be obliged to declare whether the voluntary withdrawal of a medicine or the non-renewal of its licence was due to safety reasons."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph